CAJ | 학술논문

对1998年2月至2005年12月行供者肾脏、造血干细胞联合移植(联合移植组,48例)和同一供者肾脏移植(对照组,48例)患者进行术后移植肾存活率(剔除带功死亡者)随访比较.术后1、3、5及10年,移植肾存活率联合移植组分别为98％(47/48) 、94％(45/48) 、83％(34/41)和9/17,对照组分别为98％(47/48),90％(43/48)、76％.(31/41)和7/17.慢性排斥反应的发生,联合移植组为2％ (1/48)、对照组为17％(8/48)(P＜0.05).供者造血干细胞输注能诱导肾移植患者免疫耐受产生,减少排斥反应的发生,提高患者的生存质量.
대1998년2월지2005년12월행공자신장、조혈간세포연합이식(연합이식조,48례)화동일공자신장이식(대조조,48례)환자진행술후이식신존활솔(척제대공사망자)수방비교.술후1、3、5급10년,이식신존활솔연합이식조분별위98％(47/48) 、94％(45/48) 、83％(34/41)화9/17,대조조분별위98％(47/48),90％(43/48)、76％.(31/41)화7/17.만성배척반응적발생,연합이식조위2％ (1/48)、대조조위17％(8/48)(P＜0.05).공자조혈간세포수주능유도신이식환자면역내수산생,감소배척반응적발생,제고환자적생존질량.
Ninety six female patients with chronic renal failure were randomly allocated into combination group (n =48) and control group (n =48).In combination group patients received both kidney transplantation and hematopoietic stem cell infusion,in control group patients underwent kidney transplantation only.The results showed that chronic rejection in the combination group was lower than that in the control group [2％(1/48)vs.17％ (8/48),P＜0.05)].The 1-,3-,5-and 10 y-survival rates of kidney in the combination group were 98％ (47/48),94％ (45/48),83％ (34/41) and 9/17,respectively,those in control group were 98％ (47/48),90％ (43/48),76％ (31/41) and 7/17,respectively.Infusion of donor hematopoietic stem cells can augment chimerism in early postoperative period and significantly reduce the rate of graft rejection,which is beneficial for the quality of life of the recipients.